BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251120T090000
DTEND;TZID=Europe/Vienna:20251121T123000
DTSTAMP:20260422T082933
CREATED:20241017T084331Z
LAST-MODIFIED:20250929T122752Z
UID:1966-1763629200-1763728200@esmit.eanm.org
SUMMARY:Focus on FDG PET/CT in Inflammatory and Infectious Diseases
DESCRIPTION:Inflammation comes from the Latin word inflammare\, to ignite or to set on fire – we want to ignite your interest in imaging inflammation and infection. \n\n\n\nInflammatory and infectious diseases can be clinically challenging. Many are systemic with highly variable clinical presentations and sometimes vague and non-specific symptoms and findings. Association with implanted material like artificial heart valves\, joint or vascular prostheses may hamper imaging or give rise to non-specific findings. \n\n\n\nAlthough the imaging strategy may still be considered unclarified in some settings\, [18F]FDG-PET/CT is now established as a key modality in the diagnostic workup of several inflammatory and infectious diseases. The course aims to provide the participants with an overview of the evidence and practical use of [18F]FDG-PET/CT in suspected inflammation and infection and covers the most well-established indications.  \n\n\n\nLed by European experts\, the sessions mix short overview lectures with interactive sessions to allow participants to engage in discussions and exchange experiences on daily practices with each other and the faculty. \n\n\n\nRegister nowThe course is fully booked. Please contact us at esmit@eanm.org if you would like to be added to the waiting list! \n\n\n\n\n\n\n\n\nLearning Objectives\n\n\n\n\nTo provide general insights into the use of [18F]FDG PET/CT in suspected or manifest inflammation and infection\, e.g. patient preparation and protocols\n\n\n\nTo provide insights into how and when to use [18F]FDG PET/CT in suspected or manifest specific inflammatory diseases\, e.g. vasculitis\, polymyalgia rheumatica\, other reumatologic diseases\, and  sarcoidosis\n\n\n\nTo provide insights into how and when to use [18F]FDG PET/CT in suspected or manifest specific infectious diseases\, e.g. fever and inflammation of unknown origin\, blood stream infections\, osteomyelitis and spondylodiscitis\, cardiac and vascular infections\n\n\n\nTo provide some insights into novel developments with this domain\, e.g. FAPI\, bacteria-specific tracers\, and long axial field of view scanners\n\n\n\nTo facilitate an open discussion on pro and cons of [18F]FDG PET/CT in suspected or manifest inflammation and infections\n\n\n\n\n\n\nTarget Audience\n\n\n\nNuclear medicine specialists with basic experience in reading [18F]FDG-PET/CT in inflammatory and infectious diseases.  \n\n\n\n\n\n\n\n\nProgrammeView the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nSoren HessSpeakerOdense\, Denmark \n\n\n\n\n\nOlivier GheysensSpeakerBrussels\, Belgium \n\n\n\n\n\nAyah NawwarSpeakerBristol\, UK \n\n\n\n\n\nGiorgio TregliaSpeakerLugano\, Switzerland \n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/focus-on-fdg-pet-ct-in-inflammatory-and-infectious-diseases/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Clinical Nuclear Medicine,Onsite Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251201T100000
DTEND;TZID=Europe/Vienna:20251201T110000
DTSTAMP:20260422T082933
CREATED:20250513T093530Z
LAST-MODIFIED:20251118T083337Z
UID:2534-1764583200-1764586800@esmit.eanm.org
SUMMARY:Japanese vs. European View on Targeted Radionuclide Therapy
DESCRIPTION:This event is a collaboration between ESMIT and JSNM. The aim of the webinar is to compare the approach to targeted radionuclide therapy (TRT) in Japan and in Europe. The webinar will focus on the differences in the TRT environment in Japan vs. Europe\, including regulatory science and radiation protection regulation\, and more. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nNuclear Medicine Physicians \n\n\n\n \n\n\n\nFaculty\n\n\n\n\nTatsuya HigashiSpeaker \n\n\n\nWolfgang FendlerSpeaker \n\n\n\nConrad-Amadeus VoltinModerator \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/japanese-vs-european-view-on-targeted-radionuclide-therapy/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251204T080000
DTEND;TZID=Europe/Vienna:20251205T170000
DTSTAMP:20260422T082933
CREATED:20241017T084515Z
LAST-MODIFIED:20250624T123657Z
UID:1968-1764835200-1764954000@esmit.eanm.org
SUMMARY:Nuclear Medicine in Breast Cancer Based on FOCUS Meeting 6
DESCRIPTION:Breast cancer is the most relevant cancer in women worldwide. It is the second most frequently diagnosed cancer (after lung cancer) and the first leading cause of cancer-related death in women\, being the fourth globally regardless of gender. By 2040\, breast cancer is predicted to increase to over 3 million new cases and 1 million deaths per year. \n\n\n\nStaging patients with breast cancer is challenging due to its heterogeneous nature and presentation. Imaging is of utmost importance in all clinical settings\, particularly\, in staging\, assessing therapy response\, and detecting recurrence. Despite the well-stablished usefulness of radiologic modalities\, Nuclear Medicine has demonstrated an important role to play in breast cancer\, which has been increasingly supported by strong scientific evidence. Considering the patient’s long survival\, the benefits of assessing active tumour in an accurate way\, gain major importance in these patient’s care. \n\n\n\nThe recent equipment and radiopharmaceutical developments have opened the path to improve tumour characterization through several imaging possibilities. Currently\, the challenge is to use the correct combination of equipment and tracer at the right time. Furthermore\, homogenize imaging and clinical procedures is becoming even more important. \n\n\n\nDuring this course\, the highlights from the consensus reached during the multidisciplinary EANM Focus Meeting 6 about Nuclear Medicine diagnostics and therapeutics possibilities will be comprehensively presented and discussed in a close way between the faculty and attendees. \n\n\n\n\n\n\n\nRegister nowRegistration is now open\, save yourself a seat! Register now\n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo understand breast cancer as a heterogeneous disease\, its characteristics and evolution;\n\n\n\nTo define the role of nuclear medicine techniques in different clinical settings (initial staging\, assessing therapy response\, and detecting recurrence);\n\n\n\nTo know the potential usefulness of PET tracers beyond FDG in each breast cancer subtype and use of the evolving PET technology & equipment;\n\n\n\nTo discuss future diagnostic and treatment approaches with radiopharmaceuticals.\n\n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nNuclear Medicine physicians\, Radiologists\, Medical Oncologists\, Radiation Oncologists\, Medical students\, Residents\, Nurses\, Nuclear Medicine technologists and Radiographers. \n\n\n\n \n\n\n\n\n\n\n\nProgrammeView the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nSofia VazSpeakerLisbon\, Portugal \n\n\n\n\n\nThiemo van NijnattenSpeakerMaastricht\, Netherlands \n\n\n\n\n\nPhilipp BackhausSpeakerMünster\, Germany \n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/nuclear-medicine-in-breast-cancer-based-on-focus-meeting-6/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Clinical Nuclear Medicine,Onsite Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251212T133000
DTEND;TZID=Europe/Vienna:20251212T143000
DTSTAMP:20260422T082933
CREATED:20241017T081824Z
LAST-MODIFIED:20251204T110136Z
UID:1944-1765546200-1765549800@esmit.eanm.org
SUMMARY:To AI or not to AI in Neurology: That is the Question
DESCRIPTION:This webinar will explore state-of-the-art AI approaches for advancing neuroimaging\, with a particular focus on quantitative PET. It will cover the entire imaging pipeline\, from preprocessing\, acquisition\, and tomographic reconstruction to quantification\, segmentation\, denoising\, and resolution enhancement\, demonstrating how modern AI can enable more reproducible and robust brain PET biomarkers. Through two expert presentations and practical case examples\, the webinar will showcase how AI-driven methodologies are reshaping neuroimaging research and supporting more accurate diagnosis and disease monitoring. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nLearn the principles behind AI-based quantitative PET methods\n\n\n\nUnderstand how AI can enhance each stage of the neuroimaging pipeline\, from preprocessing and reconstruction to segmentation\, denoising\, and resolution recovery.\n\n\n\nCritically assess when AI meaningfully improves neuroimaging workflows\n\n\n\nRecognize emerging opportunities and challenges in integrating AI tools into brain PET\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nNuclear physicians\, medical physicists\, imaging scientists and radiologists working in PET neuroimaging \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nPablo Aguilar FernándezModerator \n\n\n\n\n\nDimitris VisvikisSpeaker \n\n\n\n\n\nCharalampos TsoumpasSpeaker \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/to-ai-or-not-to-ai-in-neurology-that-is-the-question/
CATEGORIES:AI & Quantification,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20261231T000000
DTEND;TZID=Europe/Vienna:20261231T235900
DTSTAMP:20260422T082933
CREATED:20220901T101846Z
LAST-MODIFIED:20251016T123526Z
UID:1315-1798675200-1798761540@esmit.eanm.org
SUMMARY:Fundamentals of Research in Imaging and Theranostics – Part 1: Research Design
DESCRIPTION:UEMS EACCME has granted the accreditation of 4 CME credits for this event. \n\n\n\nThis online course is part of a long line of research methodology which is aimed at providing interested participants with information about the preclinical development and clinical translation\, as well as the design\, conductance and reporting of clinical research trials\, with a specific emphasis on radiopharmaceuticals for both diagnostic and therapeutic applications.  \n\n\n\nThese first two modules will represent part one of the course.  \n\n\n\nModule 1 will focus on the entire path from preclinical development to clinical translation of an imaging compound\, including the preclinical studies needed for the selection of a new candidate for clinical translation\, an overview of EU legislation on radiopharmaceuticals for diagnosis and therapy\, and the assessment of quality data and non-clinical data (pharmacology\, dosimetry and toxicology) for the IMP dossier.  \n\n\n\nModule 2 will be focused on the design of a proper trial. It will cover: the definition of objectives\, aims\, endpoints\, population\, statistical methods and examples of trial design schemes\, as well as dosimetry as far as healthy organs and in case of therapy tumour-absorbed dose. It will have a special focus on phase 0\, phase 1-2 trial\, early clinical phase 0-1-2 and investigator-driven clinical trial. \n\n\n\n \n\n\n\n\n\n\n\nSave yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n\n\n\n\n\n\nLearning Objectives:\n\n\n\nLearn about: \n\n\n\n\nPreclinical development and clinical translation of radiopharmaceuticals \n\n\n\nThe legislation on radiopharmaceuticals with a specific focus on the European scenario \n\n\n\nRequirements of IMPD for radiopharmaceuticals for imaging agents and theranostic/therapeutic molecules Interpretation of preclinical data to properly design and plan the clinical trial \n\n\n\nPhase 0\, phase 1 and phase 2 clinical trials with radiopharmaceuticals design \n\n\n\nPhase 0\, phase 1 and phase 2 clinical trials with radiopharmaceuticals conductance \n\n\n\nGMP\, GLP and GCP principles \n\n\n\nImportance of radioprotection and dosimetric estimates in early phase clinical trials\n\n\n\n\n\n\n\n\n\n\n\n\nTarget Audience:\n\n\n\n\nResearchers\, scientists\, nurses\, pharmacologists\, radiopharmacists\, residents and specialists in Nuclear Medicine/Oncology/Radiology who want to understand how clinical trials with radiopharmaceuticals in the early phase are unique and how the corresponding documents and trial design should be appropriately planned.\n\n\n\n\n\n\n\n\n\n\nProgrammeClick to see the full event programme.  View the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nPaola Anna ErbaUniversità degli Studi di Milano-Bicocca\, Italy \n\n\n\n\n\nSona BalogovaComenius University\, Bratislava\, Slovakia \n\n\n\n\n\nElisabeth von GuggenbergMedical University Innsbruck\, Austria \n\n\n\n\n\n\n\nMartina SolliniVita-Salute San Raffaele University\, Milan\, Italy \n\n\n\n\n\nLuigi AlojUniversity of Cambridge\, United Kingdom \n\n\n\n\n\nMeltem OcakIstanbul University\, Turkey \n\n\n\n\n\n\n\nPeter LavermanRadboud Universiteit Nijmegen\, The Netherlands \n\n\n\n\n\nJane SosabowskiQueen Mary\, University of London\, United Kingdom \n\n\n\n\n\nPetra KolencUniversity Medical Centre Ljubljana\, Slovenia \n\n\n\n\n\n\n\nClemens DecristoforoMedical University Innsbruck\, Austria \n\n\n\n\n\nPiotr GarnuszekPOLATOM\, Warsaw\, Poland \n\n\n\n\n\nRenata MikolajczakPOLATOM\, Warsaw\, Poland \n\n\n\n\n\n\n\nTheodosia MainaNCSR Demokritos\, Athens\, Greece \n\n\n\n\n\nMark KonijnenbergErasmus MC\, Rotterdam\, The Netherlands \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration Fee\n\nCourse Fee              Free \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/fundamentals-of-research-in-imaging-and-theranostics-part-1-research-design/
LOCATION:Online
CATEGORIES:Research Methods,Self-paced Online Course
END:VEVENT
END:VCALENDAR